Literature DB >> 8862165

Methodological issues in evaluating HIV prevention community planning.

D R Holtgrave1, J Harrison, R A Gerber, T V Aultman, M Scarlett.   

Abstract

To be effective, HIV prevention programs should be planned in partnership with affected communities and should be built on a solid scientific foundation. In 1994, the Centers for Disease Control and Prevention (CDC) and its prevention partners implemented HIV prevention community planning to achieve primarily these two objectives. In order to manage the community planning process effectively, extensive evaluation activities were employed at both the grantee and national level. This paper describes the first year evaluation goals and methods in detail. Throughout, reasons for collecting specific types of information and for using particular methodologies are highlighted.

Mesh:

Year:  1996        PMID: 8862165      PMCID: PMC1382051     

Source DB:  PubMed          Journal:  Public Health Rep        ISSN: 0033-3549            Impact factor:   2.792


  1 in total

Review 1.  Community planning: a national strategy to improve HIV prevention programs.

Authors:  R O Valdiserri; T V Aultman; J W Curran
Journal:  J Community Health       Date:  1995-04
  1 in total
  4 in total

Review 1.  Decision-making in HIV prevention community planning: an integrative review.

Authors:  A P Johnson-Masotti; S D Pinkerton; D R Holtgrave; R O Valdiserri; M Willingham
Journal:  J Community Health       Date:  2000-04

2.  A method to measure the costs of counseling for HIV prevention.

Authors:  R D Gorsky
Journal:  Public Health Rep       Date:  1996       Impact factor: 2.792

Review 3.  Adaptation of behavioral theory to CDC's HIV prevention research: experience at the Centers for Disease Control and Prevention.

Authors:  L C Leviton; K O'Reilly
Journal:  Public Health Rep       Date:  1996       Impact factor: 2.792

4.  Behavioral science and public health: a necessary partnership for HIV prevention.

Authors:  M Fishbein; M Guinan
Journal:  Public Health Rep       Date:  1996       Impact factor: 2.792

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.